Sunday, January 17, 2021
Germany Latest News
  • Sports
  • USA
  • Asia
  • Health
  • Life Style
  • Tech
  • Science
  • Latin America
  • Africa
  • Europe
No Result
View All Result
Germany Latest News
Home Health

BioNTech admits it will struggle to fill COVID vaccine ‘gap’

admin by admin
January 1, 2021
in Health
0
BioNTech admits it will struggle to fill COVID vaccine ‘gap’
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Ugur Sahin, co-founder of the German vaccine developer BioNTech, is hoping to be able to boost production of the BioNTech-Pfizer vaccine by February, according to an interview with the Der Spiegel news magazine published on Friday.

The BioNTech executive also said he had been surprised by the European Union’s reticence towards purchasing enough supplies of the vaccine and warned that the current vaccine availability was not looking “rosy.”

Related posts

As Germans continue to circulate, COVID death rate rises

As Germans continue to circulate, COVID death rate rises

January 16, 2021
Coronavirus vaccine: German Health Minister Jens Spahn under fire

Coronavirus vaccine: German Health Minister Jens Spahn under fire

January 6, 2021

“We are lacking other approved vaccines and we have to fill this gap with our vaccine,” the Mainz-based company founder said.

Sahin said he was hopeful that, towards the end of January, the vaccine developer would have “clarity as to whether we can produce more and how much.”

This included the plan to have a new manufacturing facility in the city of Marburg up and running in February — “far earlier than planned” — which could produce a further 250 million doses in the first six months of 2021.

BioNTech-Pfizer faces limited production capacity

With its American partners at Pfizer, BioNTech is attempting to scale up production to meet the huge demand for a global immunization program.

While several other vaccines have been given the rubber stamp in different countries, the BioNTech-Pfizer vaccine was the first to gain approval in Europe and North America.

However, production faces extra challenges due to the complex technology behind it.

Sahin highlighted two main problems hampering increased production of the vaccine.

He explained to Der Spiegel that there is a lack of available facilities that can quickly be turned over to vaccine production.

“We are trying to find new cooperation partners to produce for us. But it’s not as if there were specialized unused factories lying around across the world that could produce vaccines of the required quality from one day to the next.”

The second major problem for producing the BioNTech-Pfizer vaccine is that the high complexity of the mRNA technology does not lend itself well to easy productive adaptability.

“You can’t just switch over, from producing vaccines instead of aspirin or cough syrup. The process requires years of expertise and the appropriate structural and technological equipment,” Sahin explained.

Delayed EU approval hampers vaccine roll-out

Despite receiving emergency approval in the US and UK several weeks ago, the BioNTech-Pfizer vaccine only received EU regulatory approval just days before Christmas.

EU countries have launched large-scale vaccination programs, but there are now concerns about whether there will be sufficient doses and whether demand can be met.

Fellow co-founder, and Sahin’s wife, Özlem Türeci, told the magazine that Brussels had assumed there would be a “basket of suppliers to choose from” due to the array of different vaccines in development.

This meant the EU ended up placing a relatively low order of just 300 million doses with BioNTech-Pfizer, and not until November. The US, on the other hand, ordered 600 million doses in July.

Both Bavarian State Premier Markus Söder and leader of the business-friendly FDP party Christian Lindner have called for vaccine production to be massively stepped up.

However, Sahin pointed out in his interview that part of the problem lay with the European Commission’s previous assumptions about vaccine availability. While the EU had pre-emptively ordered vaccines from BioNTech, they had also put in orders with other producers, yet these other vaccines have still not been approved.

“There was the assumption that many more companies would come with vaccines. Apparently, there was the impression that we [the EU] will get enough, it won’t be that bad and we [Brussels] have it under control. This surprised me,” Sahin said.

Read from source: https://www.dw.com/en/biontech-admits-it-will-struggle-to-fill-covid-vaccine-gap/a-56110454

 

Previous Post

Wall Street to kick out Chinese telecom giants

Next Post

New Year’s Eve — How to make resolutions for the new year

Next Post
New Year’s Eve — How to make resolutions for the new year

New Year's Eve — How to make resolutions for the new year

RECOMMENDED NEWS

Twitter under investigation for allegedly refusing to reveal how it tracks you     – CNET

Twitter under investigation for allegedly refusing to reveal how it tracks you – CNET

2 years ago
Christie wins host Indonesia’s signature gold at Asian Games

Christie wins host Indonesia’s signature gold at Asian Games

2 years ago
Khabib presented ‘1st Russian UFC champ’ cup by hometown team, kicks off match (PHOTOS/VIDEO)

Khabib presented ‘1st Russian UFC champ’ cup by hometown team, kicks off match (PHOTOS/VIDEO)

2 years ago
Real winner of race for the European Medicines Agency

Real winner of race for the European Medicines Agency

3 years ago

FOLLOW US

  • 79 Followers

BROWSE BY CATEGORIES

  • Africa
  • Asia
  • Europe
  • Health
  • latest news
  • Latin America
  • Life Style
  • Science
  • Sports
  • Tech
  • USA

BROWSE BY TOPICS

2018 League Balinese Culture Bali United Budget Travel Champions League Chopper Bike Doctor Terawan Istana Negara Market Stories National Exam Pope Francis may mediate Gulf Crisis Solution Visit Bali
No Result
View All Result

Recent Posts

  • Kunal Kapur: I want to research more on immunity boosters in 2021
  • Coronavirus: Face mask, face shield, FFP2, N95, KN95 – what’s the difference?
  • Bundesliga: Borussia Dortmund’s home woes continue after Marco Reus penalty miss
  • As Germans continue to circulate, COVID death rate rises
  • Trump’s final full week in office ends with the nation in disarray

Categories

  • Africa
  • Asia
  • Europe
  • Health
  • latest news
  • Latin America
  • Life Style
  • Science
  • Sports
  • Tech
  • USA

Tags

2018 League Balinese Culture Bali United Budget Travel Champions League Chopper Bike Doctor Terawan Istana Negara Market Stories National Exam Pope Francis may mediate Gulf Crisis Solution Visit Bali
German Constitutional Court upholds ban on anti-lockdown protest
latest news

German Constitutional Court upholds ban on anti-lockdown protest

by admin
December 6, 2020
0

An anti-lockdown group had filed an urgent court appeal hoping to allow 20,000 people to gather in Bremen. Despite the...

Read more

Recent News

  • Kunal Kapur: I want to research more on immunity boosters in 2021
  • Coronavirus: Face mask, face shield, FFP2, N95, KN95 – what’s the difference?
  • Bundesliga: Borussia Dortmund’s home woes continue after Marco Reus penalty miss

Category

  • Africa
  • Asia
  • Europe
  • Health
  • latest news
  • Latin America
  • Life Style
  • Science
  • Sports
  • Tech
  • USA

Recent News

Kunal Kapur: I want to research more on immunity boosters in 2021

Kunal Kapur: I want to research more on immunity boosters in 2021

January 16, 2021
Coronavirus: Face mask, face shield, FFP2, N95, KN95 – what’s the difference?

Coronavirus: Face mask, face shield, FFP2, N95, KN95 – what’s the difference?

January 16, 2021
  • About
  • Advertise
  • Careers
  • Contact

© 2021 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result
  • Home
  • Sports

© 2021 JNews - Premium WordPress news & magazine theme by Jegtheme.